Xijing Hospital: Breast Neoplasms trials

The registry lists 26 Breast Neoplasms studies with Xijing Hospital as lead sponsor. 7 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 10Phase 3 2Phase 4 1No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast CancerNot yet recruitingNCT07466303Phase 2
• Study on the Cosmetic Outcome and Safety Evaluation of 3D Printed Biodegradable Biological Mesh for One-Stage Breast Reconstruction After Radical MastectomyRecruitingNCT07365267Not applicable
• Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast CancerRecruitingNCT07012720Not applicable
• Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled TrialRecruitingNCT06938360Not applicable
• Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast CancerRecruitingNCT06914440Phase 2
• A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast CancerNot yet recruitingNCT06769919Phase 2/3
• RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast CancerNot yet recruitingNCT05134519Phase 2
• Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast CancerActive, not recruitingNCT05558722Phase 2Results posted
• Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast CancerActive, not recruitingNCT07532096Not applicable
• Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast CancerActive, not recruitingNCT07498400Not applicable
• Comparison of Safety and Patients-Reported Outcomes Between Single-Port Endoscopic and Conventional Nipple-Sparing Mastectomy With Immediate Implant ReconstructionCompletedNCT07410728
• A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast CancerCompletedNCT07162051Phase 2
• A Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With SurgeryActive, not recruitingNCT07071402Not applicable
• Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast CancerCompletedNCT05444998Phase 2
• PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast CancerStatus unknownNCT05346107Phase 2
• Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum DeviceStatus unknownNCT04239105
• Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast CancerStatus unknownNCT04182568Phase 4
• Sentinel Lymph Node Biopsy in Early Breast Cancer: a Real-world Multicenter Cross-sectional Study (CABS001 Study)Status unknownNCT04156841
• Breast Cancer Treatment Based on Organ-like CultureStatus unknownNCT03925233
• Safety Study of 3D Printing Personalized Biodegradable Implant for Breast ReconstructionCompletedNCT03348293Phase 1
• Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast CancerStatus unknownNCT03273595Phase 2
• 68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and Applications in Glioma Patients or Breast Cancer PatientsStatus unknownNCT02327442
• Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast CancerStatus unknownNCT02188693
• Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast CancerStatus unknownNCT02012634
• Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast CancerStatus unknownNCT01479036Phase 3
• Neoadjuvant Endostatin and Chemotherapy for Breast CancerCompletedNCT00604435Phase 2